Compare Archer-Daniels-Midland Co (ADM) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Cassava Sciences Inc — how do they compare? Archer-Daniels-Midland Co trades at $80.46 (market cap $38.78B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Archer-Daniels-Midland Co is far larger — about 812.1× Cassava Sciences Inc's market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| ADM | FLNA | |
|---|---|---|
Market Cap | $38.78B | $47.75M |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $4.64 |
52-Week Low | $56.00 | $0.87 |
Enterprise Value | $47.03B | -$34.93M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.41, down 1.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.84, exceeding expectations, and raised its full-year outlook, driven by biofuels and crushing margins. Valuation ratios like P/E of 21.98 and P/S of 0.48 suggest reasonable pricing relative to peers. Cash flow improved in 2025 with net cash flow of $1.58 billion.
The outlook is positive with analyst consensus price target of $88.00, implying upside. Key opportunities include growth in AgTech and biofuels, while risks involve execution challenges and volatile commodity markets. The stock offers a dividend yield supported by consistent payments, but investors should monitor margin pressures from input costs.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
